2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Metcela Inc., Japan

Revolutionizing the way we treat heart failure

Company Type

Biotechnology

Startup

Company Name /Metcela Inc.

Company Website /Metcela.com

Startup year /2016

Amount of Capital /-

No. of workers /17 FTE

Stage

Startup

Presenter

Name /H. Joon Paek, Ph.D.

Title /Vice President, Corporate Development

Email /j.paek@metcela.com

Telephone /(Work) +81-44-201-1376

Fax /+81-50-3730-8153

Mobile /+81-80-7062-1123

About the Team

Metcela is a clinical stage biotech startup in Japan. At Metcela, we are developing an innovative, clinically viable and effective cell therapy for heart failure using a specific population of fibroblasts found in the heart, called VCAM-1-positive cardiac fibroblasts or “VCFs”. Since the first discovery of VCFs’ therapeutic effects for heart failure by one of our co-founders, we have been working closely with a group of cardiologists, researchers and delivery device experts to develop commercially viable therapeutics and procedures.

Brief Description of main products or services

Our approach to heart failure therapy is quite unique from others’ previous attempt to simply replenish cardiomyocytes in the infarcts. Instead, we aim to re-establish favorable microenvironments through lymphangiogenesis and stimulate endogenous cardiomyocytes to regenerate damaged cardiac tissue, by VCFs.

The ideal route of cell delivery to the heart tissues is transendocardial injection using a catheter. The two main issues with the previous delivery systems were: 1) insufficient visualization and 2) low retention rates of the cells. Metcela’s delivery catheter addresses these deficiencies by implementing 3D electromapping and customized injection needle. Improved visualization is imperative for precise determination of the infarcted areas and targeted delivery to maximize therapeutic benefits.

The efficacy of VCF technology has been confirmed in animal heart failure models. Especially for the porcine heart failure model study, Metcela’s clinical injection catheter was used, and the 12-week post-op observations revealed strong efficacy with more than 35% relative EF improvement from the baseline EF at pre-injection. The therapeutic effects of VCFs as well as improved targeting and cell retention jointly contributed to the unprecedented outcome in the porcine heart failure model.

Metcela is currently preparing to initiate a phase I clinical trial in Japan in the early 2021.

Contact Person

Name /H. Joon Paek, Ph.D.

Phone /(Work) +81-44-201-1376

Email /j.paek@metcela.com